The Effect of Antithrombin III-Independent Thrombin Inhibitors and Heparin on Fibrin Accretion onto Fibrin-Coated Polyethylene

 

PDF Download Buy Article Permissions and Reprints

Summary

Prosthetic vascular grafts become coated with a layer of fibrin that contributes to graft thrombosis and occlusion. We compared the effect of antithrombin III-independent inhibitors of thrombin with heparin for their ability to prevent fibrin accretion onto a model of a vascular graft formed in vitro by coating polyethylene tubing with thrombin bound to a layer of polymerized fibrin. Equivalent antithrombin concentrations of heparin, D-Phe-Pro-Arg CH₂Cl (PPACK), recombinant hirudin (r-hirudin), and Hirulog-1 were added to barium chloride-adsorbed plasma containing radiolabelled fibrinogen. Whereas, PPACK and r-hirudin persistently inhibited fibrin accretion, the inhibition by heparin was transient. Hirulog-1 had no effect on early fibrin accretion and was actually associated with enhanced accretion at 30 min (control 11.7 ± 2.0 μg fibrin/cm²; Hirulog-1, 18.4 ± 3.5 μg fibrin/cm², p <0.001). Both Hirulog-1 and r-hirudin displaced radiolabelled thrombin from the fibrin surface. Whereas hirudin-thrombin complexes are stable, Hirulog-1 produces only transient inhibition of the displaced thrombin thereby accounting for the enhanced fibrin accretion with this anticoagulant. These studies show that the antithrombin III-independent inhibitors, r-hirudin and PPACK, are more effective inhibitors of fibrin accretion onto fibrin-coated polyethylene than heparin or Hirulog-1. In addition, they emphasize the importance of determining the ability of anticoagulants to displace thrombin from fibrin and to form stable thrombin-inhibitor complexes; lack of stability of thrombin-inhibitor complexes must be countered by levels of anticoagulant that are adequate to maintain its effectiveness.

• References

• 1 Forbes CD. Thrombosis and artificial surfaces. Clin Haematol 1981; 10: 653-666
  PubMedGoogle Scholar
• 2 Nichter LS, Bindiger A. Improving micrograft patency. Microsurgery 1988; 9: 235-241
  CrossrefPubMedGoogle Scholar
• 3 Berger K, Sauvage LR, Rao AM, Wood SJ. Healing of arterial prostheses in man: Its incompleteness. Ann Surg 1972; 175: 118-127
  CrossrefPubMedGoogle Scholar
• 4 Dryjski M, Swedenborg J, Wasiutynski A. Uptake and inactivation of thrombin on aortic endothelium and neo-intima. Eur Surg Res 1985; 17: 1-9
  PubMedGoogle Scholar
• 5 Wilner GD, Danitz MP, Mudd MS, Hsieh K-H, Fenton JW II. Selective immobilization of α-thrombin by surface-bound fibrin. J Lab Clin Med 1981; 97: 403-411
  PubMedGoogle Scholar
• 6 Packham MA. The behaviour of platelets at foreign surfaces. Proc Soc Exp Biol Med 1988; 189: 261-274
  CrossrefPubMedGoogle Scholar
• 7 Johnson PC. Platelet-mediated thrombosis in microvascular surgery: New knowledge and strategies. Plast Reconstr Surg 1990; 86: 359-367
  CrossrefPubMedGoogle Scholar
• 8 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
  CrossrefPubMedGoogle Scholar
• 9 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623
  CrossrefPubMedGoogle Scholar
• 10 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-10425
  PubMedGoogle Scholar
• 11 Noon GP, DeBakey ME. DeBakey dacron prosthesis and filamentous velour graft. In: Vascular Grafts. Sawyer PN, Kaplitt MJ. (eds). Appleton-Century-Crofts; New York: 1976: 177-184
  Google Scholar
• 12 Rubens FD, Brash JL, Weitz JI, Kinlough-Rathbone RL. Interactions of thermally-denatured fibrinogen on polyethylene with plasma proteins and platelets. J Biomed Mater Res 1992; 26: 1651-1663
  CrossrefPubMedGoogle Scholar
• 13 Rubens FD, Brash JL, Weitz JI, Kinlough-Rathbone RL. Fibrin-coated polyethylene: A model for thrombogenic neointima on biomaterials. Fourth World Biomaterials Congr. 1992 (Abstr).
  PubMedGoogle Scholar
• 14 Straughn WIII, Wagner RH. A simple method for preparing fibrinogen. Thromb Diath Haemorrh 1966; 16: 198-205
  PubMedGoogle Scholar
• 15 Degryse E, Caroline E. Influence of storage conditions on the activity of recombinant hirudin. Thromb Res 1991; 61: 87-89
  PubMedGoogle Scholar
• 16 Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951; 37: 316-321
  PubMedGoogle Scholar
• 17 Owren PA. A quantitative one-stage method for the assay of prothrombin. J Clin Lab Invest 1949; 1: 81-83
  CrossrefPubMedGoogle Scholar
• 18 Hatton MWC. Studies on the coagulant enzyme from Agkistrodon rhodostoma venom. Biochem J 1973; 131: 799-807
  CrossrefPubMedGoogle Scholar
• 19 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
  CrossrefPubMedGoogle Scholar
• 20 Lawrie JS, Ross J, Kemp GD. Purification of fibrinogen and the separation of its degradation products in the presence of calcium ions. Biochem Soc Trans 1979; 7: 693-694
  CrossrefPubMedGoogle Scholar
• 21 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
  CrossrefPubMedGoogle Scholar
• 22 Berliner LJ, Sugawara Y, Fenton JWII. Human a-Thrombin binding to nonpolymerized fibrin-sepharose: Evidence for an anionic binding region. Biochemistry 1985; 24: 7005-7009
  CrossrefPubMedGoogle Scholar
• 23 Mosesson MW. Fibrin polymerization and its regulatory role in hemostasis. J Lab Clin Med 1990; 116: 8-17
  PubMedGoogle Scholar
• 24 Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-230
  PubMedGoogle Scholar
• 25 Fenton JWII, Villanueva GB, Ofosu FA, Maraganore JM. Thrombin inhibition by hirudin: How hirudin inhibits thrombin. Haemostasis 1991; 21 (Suppl. 01) 27-31
  PubMedGoogle Scholar
• 26 Schmitz T, Rothe M, Dodt J. Mechanism of the inhibition of a-thrombin by hirudin-derived fragments hirudin (1-47) and hirudin (45-65). Eur J Biochem 1991; 195: 251-256
  CrossrefPubMedGoogle Scholar
• 27 Kaminski M, McDonagh J. Inhibited thrombins. Interactions with fibrinogen and fibrin. Biochem J 1987; 242: 881-887
  CrossrefPubMedGoogle Scholar
• 28 Kettner C, Shaw E. D-Phe-Pro-Arg CH₂C1. A selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
  CrossrefPubMedGoogle Scholar
• 29 Krupski WC, Bass A, Kelly AB, Marzee UM, Hanson SR, Harker LA. Heparin-resistant thrombus formation by endovascular stents in baboons. Interruption by a synthetic antithrombin. Circulation 1990; 82: 570-577
  CrossrefPubMedGoogle Scholar
• 30 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101
  CrossrefPubMedGoogle Scholar
• 31 Kline T, Hammond C, Bourdon P, Maraganore JM. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem Biophys Res Commun 1991; 177: 1049-1055
  CrossrefPubMedGoogle Scholar